Status:
RECRUITING
Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV
Lead Sponsor:
University of Seville
Collaborating Sponsors:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions:
HCV Infection
Eligibility:
All Genders
Brief Summary
Background: Currently used direct-acting antivirals (DAA) share pharmacokinetic pathways with many comedications commonly used in patients with chronic hepatitis C virus (HCV) infection, therefore dru...
Eligibility Criteria
Inclusion
- Treatment naive patients who received therapy with GLE/PIB or SOF/VEL between April 1st, 2018, and July 1st, 2023, receiving ≥ 1 comedication or recreational drug.
- Attended in a hospital with electronic clinical records allowing access to all clinical visits and prescribed medications, both in all hospitals and in primary care institutions of the corresponding Spanish region during the study period.
Exclusion
- Patients who meet any of the following criteria will be excluded from the study:
- HCV treatment-experienced patients will be excluded.
- Patients without any comedication or recreational drug use
- Those who have attended private health care
Key Trial Info
Start Date :
April 30 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
728 Patients enrolled
Trial Details
Trial ID
NCT06928259
Start Date
April 30 2025
End Date
March 1 2026
Last Update
April 15 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Unidad de Enfermedades Infecciosas Hospital Universitario Puerto Real.
Cadiz, Spain
2
Unidad de Enfermedades Infecciosas. Hospital Universitario Reina Sofía de Córdoba.
Córdoba, Spain
3
Unidad de Enfermedades Infecciosas. Hospital Universitario Juan Ramón Jiménez.
Huelva, Spain
4
Departamento de Medicina. Universidad de Sevilla Hospital Universitario Virgen de Valme.
Seville, Spain